JOINN's stock price surged 5.39% during intraday trading on Thursday, reflecting strong investor confidence in the company's growth prospects.

The movement follows the company's forecast of net profit attributable to shareholders for the first half of 2026 to be between A$600 million and A$900 million, representing a year-on-year increase of approximately 884.9% to 1377.4%. JOINN attributes this significant performance growth primarily to rising market prices for its biological assets and their natural growth.

JOINN is recognized as a leading CRO in safety assessment with the largest stock of research monkeys, holding over 50,000 crab-eating macaques in its inventory. Recent industry reports indicate research monkey prices have surged to as high as A$200,000 per animal due to severe supply constraints colliding with new demand pressures from accelerated drug development. The entire CRO industry is currently in an upturn phase, with JOINN reporting new order growth of 111.6% year-on-year in Q1 2026 and a 40.9% increase in total backlog.